Researcher Tabata from Pharmacology BU to Present a Poster at the 84th Annual Meeting of the Japanese Cancer Association

2025.09.09

Our researcher, Ryotaro Tabata from the Pharmacology Business Unit, will present a poster at the 84^th Annual Meeting of the Japanese Cancer Association, to be held from September 25 to 27, 2025, in Kanazawa city, Ishikawa prefecture, Japan.
If you plan to attend the conference, we encourage you to join the session and hear the presentation.

Conference Name: the 84^th Annual Meeting of the Japanese Cancer Association

Date & Time: Saturday, September 27th, 16:15 – 17:00 (JST)

Location: Motenashi Dome Underground Plaza

Title: Establishment of a TME-resembling in vitro assay system using freshly isolated human tumoroids

Poster number: P-3155

Presenter: Ryotaro Tabata, Pharmacology Business Unit

Presentation Summary
Conventional single-cell culture and 2D multicellular culture systems have long been used in the development of novel anticancer therapies, but they fail to sufficiently mimic the complex and heterogeneous tumor microenvironment (TME) of human cancers, making them inadequate for predicting clinical efficacy. Therefore, there is an urgent need to establish in vitro preclinical models that enable drug efficacy profiling under physiologically relevant conditions. To address this, we developed an assay system in which tumor tissues obtained from surgical resections are processed into patient-derived tumoroids within 24 hours and evaluated for drug responses. In this assay system, not only cancer cells but also tumor-associated cell types, such as cancer-associated fibroblasts (CAFs) and tumor-infiltrating lymphocytes (TILs), were preserved throughout the evaluation period. Moreover, the pharmacological effects of existing drugs could be reliably assessed using tumoroid viability as a readout. These findings suggest that our assay system represents a highly valuable platform for predicting the clinical efficacy of novel anticancer candidates.

Axcelead DDP’s Soulution
At Axcelead DDP, we have established a unique system for obtaining fresh human cancer tissues, which serve as an extremely valuable tool in drug discovery research. Using these fresh human cancer tissues, we have developed an in vitro evaluation system that preserves intercellular communication and reproduces patient-specific tumor environments, providing a highly useful platform for predicting the clinical efficacy of novel drug candidates.
In addition to this evaluation system, Axcelead DDP provide comprehensive support tailored to diverse research needs — not only utilizing fresh cancer tissues but also conducting pharmacological efficacy testing with cancer organoids and orthotopic transplantation models, as well as performing mechanism-of-action (MOA) analysis and biomarker discovery through multi-omics approaches.
If you are interested in our evaluation systems or in collaborating on drug discovery projects, please feel free to contact us.